Topline data were announced from two phase 3 studies evaluating setrusumab in patients with osteogenesis imperfecta.

NextCure, Inc. has presented new preclinical data at the Brittle Bone Society Meeting showing that its novel anti-Siglec-15 antibody, NC605, significantly improves bone microarchitecture and reduces ...

Ultragenyx Pharmaceutical said on Monday that late-stage studies showed its drug for a type of genetic bone disease failed to ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates ...

Ultragenyx Pharma announces phase 3 Orbit & Cosmic results for setrusumab in osteogenesis imperfecta: Novato, California Wednesday, December 31, 2025, 18:00 Hrs [IST] Ultragenyx P ...

Researchers have successfully regenerated damaged skull bones in mice by creating a freestanding, biomimetic scaffold that combines a piezoelectric framework and the growth-promoting properties of a ...

Osteogenesis imperfecta (OI) is the most common genetic form of brittle bone disease and results in defects of both bone and connective tissue. OI patients can have significant problems with mobility ...

Ultragenyx Pharmaceutical said on Monday late-stage studies showed its experimental drug for a type of genetic bone disease failed to reduce the number of fractures that occurred per year. Shares of ...